The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous systemincluding psychiatric drugsare assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine’s (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA’s new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future.
Bu e-kitabı satın alın ve 1 tane daha ÜCRETSİZ kazanın!
Dil İngilizce ● Biçim PDF ● Sayfalar 88 ● ISBN 9780309148849 ● Editör Bruce Altevogt & Miriam Davis ● Yayımcı National Academies Press ● Yayınlanan 2010 ● İndirilebilir 3 kez ● Döviz EUR ● Kimlik 7141514 ● Kopya koruma Adobe DRM
DRM özellikli bir e-kitap okuyucu gerektirir